Ask a healthcare AI team what makes their product defensible and you'll usually hear about the model, the data, or the accuracy numbers.
Those matter. But they're also the parts of the stack that are commoditizing fastest. The model you're proud of today is a line item next year.
The durable advantage in clinical AI is somewhere less glamorous: whether the tool actually fits how clinicians work, and whether they trust it enough to use it when they're slammed. That's the moat. And it's hard to copy because it can't be bought — it has to be understood.
Why the model isn't the moat
Foundation models keep getting better and cheaper, and most clinical AI products are a thin layer on top of someone else's. If your edge is "we use a good model," so does your competitor, by next quarter. Accuracy on a benchmark is table stakes, not a differentiator.
What doesn't commoditize is the hundred small decisions about where the tool sits in the day, what it asks of an exhausted clinician, and how it behaves when the input is messy. Those decisions require knowing the work — not having read about it.
What "workflow fit" actually means
It isn't a smoother UI. In hospital medicine, fit means:
- The tool lives where the work already happens, not in a separate tab nobody opens.
- It removes a step instead of adding one. A second documentation path is where good tools go to die.
- It fails safely and visibly, so a rushed clinician isn't quietly trusting a wrong answer.
- It respects that the user has thirty seconds and seventeen other patients.
None of that shows up in a demo. All of it shows up in week three of a deployment — which is exactly when adoption is won or lost.
Trust is the other half of the moat
A clinically correct tool that clinicians don't trust is a clinically useless tool. Trust comes from a product behaving predictably under pressure, being honest about uncertainty, and never making someone look bad in front of a patient or an attending. Earn it and you get adoption that's genuinely sticky. Lose it once and you usually don't get a second look.
What this means if you're building or investing
If you're building: put someone who actually does the clinical work close to your product decisions — not as a logo on the advisor page, but in the room when you decide what the tool asks of a user. The teams that win in clinical AI tend to have clinical reality baked into the product, not bolted on.
If you're investing: discount the model claims and the accuracy slide. Spend your diligence on workflow fit, adoption at real sites, and whether clinicians would choose the tool if no one made them. That's where the defensibility actually is — and where most diligence isn't looking.
The model is the easy part to build, and the easy part to copy. The moat is everything around it that requires understanding the work.
Prabhat Garg, M.D. is a practicing hospitalist and clinical AI strategy advisor. He helps health systems, health-tech companies, and investors decide what clinical AI to buy, build, avoid, and deploy.